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Abstract 
Objective 
AA amyloidosis is a serious complication of persistent inflammation, which, untreated will 
progress to renal failure and death. Effective suppression of the underlying inflammatory 
disease is the focus of treatment. However, in approximately 20% of cases the underlying 
condition remains uncertain, presenting a dilemma as to choice of treatment.  
Methods 
We conducted a retrospective study of a cohort of 11 patients diagnosed with AA amyloidosis 
of unknown aetiology, who had been empirically treated with anakinra. 
Results 
In anakinra-responders, median pre-treatment SAA was 74 (IQR 34–190) mg/L, and median 
on-treatment SAA was 6 (4–16) mg/L (p=0.0047), with the response having been maintained 
for a median on-treatment follow-up of 1.8 (1–7.6) years. Six dialysis patients were treated 
effectively and safety with 100mg anakinra three times weekly post-dialysis. Four patients 
remained well on daily anakinra post-renal transplant. Five anakinra-responders showed 
regression and three showed stabilisation of amyloid load on serial SAP scintigraphy. 
Conclusion 
This small cohort shows that even in potentially high risk cases with organ damage secondary 
to AA amyloidosis or in the presence of a renal graft, anakinra, when used appropriately and 
carefully monitored, has proved remarkably effective and well tolerated. Longer follow-up of 
this off-label use is required. 
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CKD      Chronic kidney disease 
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AA amyloidosis is a serious complication of persistent inflammation, which, untreated will 
progress to renal failure and death [1]. Effective suppression of the underlying inflammatory 
condition can halt organ damage or even lead to improved organ function [2], and this is 
therefore the focus of treatment. However, recently published data from the National 
Amyloidosis Centre (NAC) in the United Kingdom (UK) showed that in approximately 20% 
of cases the underlying inflammatory disease is uncertain at the time of diagnosis of 
amyloidosis (Lane et al, 2017, Amyloid, in press);  furthermore, according to unpublished data 
from the same centre, the underlying disorder remained uncharacterised after extensive 
investigation in about 7% of these cases, and a review of Spanish data reported 9 to 13% of 
cases having no final diagnosis of the underlying inflammatory disease [3]. This creates a 
dilemma as to the choice of empirical treatment.  
Use of corticosteroids in these cases is problematic; the presence of AA amyloidosis points to 
a chronic, rather than an episodic, inflammatory disorder and chronic immunosuppression in 
this already vulnerable patient group is not only unlikely to address the underlying 
inflammation, but is likely to contribute significant morbidity due to side effects. Colchicine 
works well in in a minority of patients and may provide an effective and low-cost alternative 
to steroids. However, a high proportion of patients fail to benefit from a therapeutic trial and 
some experience intolerable gastrointestinal side effects thereby precluding effective long term 
treatment.  
Interleukin (IL)-1α and IL-1β are potent pro-inflammatory cytokines implicated in a variety of 
chronic inflammatory and autoinflammatory disorders. Both are ligands for the IL-1 receptor; 
the activity of both cytokines is inhibited by IL-1Ra, the naturally occurring IL-1 receptor 
antagonist. Anakinra (Kineret®) is a recombinant, non-glycosylated analogue of the 
interleukin IL-1 receptor antagonist. It is a licensed treatment for rheumatoid arthritis and 
CAPS [4], but is used off-license in several other inflammatory diseases such as tumor necrosis 
factor (TNF) receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency 
(MKD), colchicine-resistant familial Mediterranean fever (crFMF) and Schnitzler’s syndrome 
with encouraging medium term safety and efficacy [5].  
Aims 
 
We report the result of empirical treatment with anakinra in a cohort of 11 patients with AA 
amyloidosis of unknown aetiology, at a single national referral centre. 
 
Patients and methods 
 
Patients and diagnosis 
 
All 11 patients were referred to the UK NAC for diagnosis, management advice and disease 
monitoring. All had been investigated locally in order to characterise the underlying 
inflammatory condition, without success, including Sanger sequencing at the NAC to rule out 
known monogenic autoinflammatory disorders. Investigation plans were individually tailored 
- the most appropriate tests were performed based on medical history and examination, as is 
advocated in investigation of pyrexia of unknown origin [6]. Almost all patients underwent 
computed tomography (CT) or positron emission tomography (PET) - CT scans and full details 
of relevant tests are provided as supplemental material. Patients gave written informed consent 
for retrospective analysis and publication of their clinical data (REC reference number 
06/Q0501/42). 
Histology and immunohistochemistry 
 
The presence of amyloid in tissue sections was confirmed by a modified version of the alkaline-
alcoholic Congo red method [7]. Formalin-fixed deparaffinised tissue sections, 6-8 µm thick, 
were stained and visualised under bright field and polarised light. Immunohistochemical 
staining of formalin fixed de-paraffinised 2 m sections of amyloidotic tissue were performed 
using commercial monoclonal antibodies to determine the amyloid fibril type [8]. Positive and 
negative controls were used in each run.  
SAP scintigraphy 
 
This nuclear medicine technique involves the intravenous injection of highly purified serum 
amyloid P component (SAP) which has been radio-labelled with the gamma emitting isotope 
123I; The radioisotope localises rapidly and specifically to visceral amyloid deposits in 
proportion to the amount of amyloid present [9], with 100% diagnostic sensitivity in AA 
amyloidosis [10]. 
Serum amyloid A protein (SAA) assay 
 
SAA was measured in serum by latex nephelometry (BNII autoanalyser; Dade Behring, 
Marburg, Germany). The lower limit of detection was 0.7 mg/L, with an inter-assay coefficient 
of variance of 2.6% at 15 mg/L and 3.7% at 80 mg/L.  Standardisation of the assay was based 
on the respective WHO International Reference Standards, 1987. 
Definition of response to treatment 
 
Complete response or remission (CR) was defined as normalisation of SAA (< 10 mg/L) and 
resolution of chronic disease symptoms and flares/exacerbations. A partial response (PR) was 
defined as improvement in, but not normalisation of, SAA and/or an improvement in disease 
symptoms. Non-responders (NR) had no significant improvement in either or both domains. 
Statistical analysis  
 
Mann Whitney tests and Kaplan-Meier analyses were performed using GraphPad Prism®. 
Results are presented as median and interquartile range (IQR) unless otherwise stated. 
Results 
 
Whole cohort characteristics 
 
Table 1 summarises patient characteristics. The total median follow-up time for this cohort was 
7.7 (3.5–8.2) years; the median duration of treatment with anakinra was 1.6 (0.6–7.4) years. 
Four patients are deceased (patients 7, 9, 10 and 11), with cause of death unrelated to anakinra 
use; one patient was lost to follow-up (patient 6) and the rest are alive and under active follow-
up. Further patient clinical detail may be found in the supplementary information. 
[Table 1 near here] 
Response to anakinra 
 
Patients 1 to 9 had either CR or PR to anakinra, whilst patients 10 and 11 were NR (Table 1). 
SAA was measured serially before and during anakinra treatment. Median pre-treatment SAA 
(the median of all available SAA measurements prior to commencing anakinra) for the whole 
cohort was 116 (39-238) mg/L. SAA was measured at a median of 17 (4–28) days after 
commencing anakinra. For the whole cohort, including patients 10 and 11 who were NR, the 
median on-anakinra SAA (i.e. the median of all SAA measurements whilst on anakinra) was 9 
(4–62) mg/L. In the patients considered responders, median pre-treatment SAA was 74 (34–
190) mg/L, and the median on-treatment SAA was 6 (4–16) mg/L. Both comparisons were 
statistically significant (p=0.0047). In responders the effect has been maintained for a median 
on-treatment follow-up of 1.8 (1–7.6) years. Individual median pre- and on-treatment responses 
are shown in Figure 1. Treatment was well-tolerated, the only adverse events being the known 
transient injection site reactions [4]. 
[Figure 1 near here] 
Renal function 
 
Patients 7, 8 and 9 were in end-stage renal failure (ESRF) at first presentation. At the time of 
commencing anakinra, patients 4, 5, 8, 9 and 11 were in ESRF; patients 1, 3, 6 and 10 had 
acceptable renal excretory function but were severely nephrotic, all having > 10g urine 
protein/24 hours; and patients 2 and 7 were in chronic kidney disease (CKD) stage 3, post renal 
transplant. Over the follow-up period, patients 4, 5 and 8 also underwent renal transplantation. 
Amyloid recurred in the graft of patient 7 only. Patients 2, 4 and 8 remain stable and well on 
100mg daily anakinra post-transplant. Patient 5 stopped anakinra prior to transplant and has 
not recommenced as his acute phase response is reasonably controlled on post-transplant 
immunosuppression. Patient 7 continued anakinra therapy until her sudden cardiac death (in 
the absence of cardiac amyloidosis). Patients on dialysis were treated with 100 mg anakinra 
three times weekly after dialysis. Patient 3 had a serum creatinine within the normal range 
before commencing anakinra, but had a protein leak of 10.5 g/24 hours. Six months after 
starting anakinra, proteinuria improved to 7.2 g and one year later had fallen to 1.9 g, with 
stable CKD. 
Monitoring of amyloid deposits 
 
Eight of nine responders had serial SAP scans over the follow-up period, with five (patients 3, 
4, 5, 7 and 8) showing regression and three (patients 1, 2 and 6) showing stabilisation of 
amyloid load, i.e. no new accumulation. Figure 2 shows the serial SAP scans of patients 4 and 
8, demonstrating amyloid regression after treatment with anakinra. 
[Figure 2 near here] 
Discussion 
 
AA amyloidosis is a potentially reversible cause of proteinuric renal disease. Historically 
treatment has been more successful than in other types of systemic amyloidosis but has relied 
completely on diagnosis of the underlying condition and targeted anti-inflammatory 
treatments. However, choice of treatment to suppress inflammation in the absence of a clear 
underlying disease is difficult, and patients with AA amyloidosis of unknown aetiology remain 
at considerable risk of succumbing to ESRF or losing their renal grafts if they had already 
received transplants. An empirical trial of cytokine blockade can be highly effective in these 
patients and give clues as to the underlying pathological pathways, but outside experienced 
centres its use is very limited due to financial constraints and concerns about possible side 
effects and off- licence use. These concerns are even more potent in the context of renal failure, 
the commonest manifestation of AA amyloidosis.  
Nonetheless this small series demonstrates that a therapeutic trial of anakinra is worth trying 
given its potentially dramatic effect, rapid onset, and excellent safety profile even in the context 
of organ failure and transplantation. It is also more cost-effective than the newer 
immunomodulators. Current data suggest it has a better long term safety profile than high dose 
corticosteroids, other anti-cytokine therapies or immunosuppressive drugs [11, 12]. In this 
series one patient with human immunodeficiency virus (HIV) and previously treated 
pulmonary tuberculosis (TB) tolerated the treatment well. The summary of product 
characteristics for anakinra states that it must not be used in patients with severe renal 
impairment [4]. Nonetheless in this series, six patients with ESRF have demonstrated that 
dosing three times per week post-dialysis provides clinically effective treatment 
unaccompanied by increased serious infection. There have been concerns about the additional 
risks of adding anakinra to the immunosuppression associated with solid organ transplantation 
but the data shown here on five patients (median age 36, median follow up 4.4 years) suggests 
a favourable risk benefit profile in these rare cases. 
This small cohort shows that even in potentially high risk cases with organ damage secondary 
to AA amyloidosis, immune deficiency due to previous immunosuppression and/or nephrotic 
syndrome, anakinra, when used appropriately and carefully monitored, has proved remarkably 
effective and well tolerated. Although longer term follow-up of this off-label use is clearly 
required these data suggest that carefully monitored empirical trials of single cytokine 
suppression can have transformative effects in selected cases. 
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